Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

No effects of gluten in non-celiac gluten sensitivity after carbohydrate reduction

A study in the issue of Gastroenterology reports no effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates.

News image

Patients with non-celiac gluten sensitivity do not have celiac disease but their symptoms improve when they are placed on gluten-free diets.

Dr Jessica Biesiekierski and colleagues from Australia investigated the specific effects of gluten after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates fermentable, oligo-, di-, monosaccharides, and polyols in subjects believed to have non-celiac gluten sensitivity.

The researchers performed a double-blind cross-over trial of 37 subjects with non-celiac gluten sensitivity and irritable bowel syndrome, but not celiac disease.

Participants were randomly assigned to groups given a 2-week diet of reduced fermentable, oligo-, di-, monosaccharides, and polyols, and were then placed on high-gluten, low-gluten, or control diets for 1 week, followed by a washout period of at least 2 weeks.

Gluten-specific effects were observed in only 8% of participants
Gastroenterology

The doctors assessed serum and fecal markers of intestinal inflammation/injury and immune activation, and indices of fatigue.

The team reported that 22 participants then crossed over to groups given gluten, whey, or control diets for 3 days.

Symptoms were evaluated by visual analogue scales.

In all participants, gastrointestinal symptoms consistently and significantly improved during reduced fermentable, oligo-, di-, monosaccharides, and polyols intake, but significantly worsened to a similar degree when their diets included gluten or whey protein.

The researchers observed gluten-specific effects in only 8% of participants.

There were no diet-specific changes in any biomarker.

The team found that during the 3-day rechallenge, participantsí symptoms increased by similar levels among groups.

Gluten-specific gastrointestinal effects were not reproduced.

An order effect was observed.

Dr Biesiekierski's team, "In a placebo-controlled, cross-over rechallenge study, we found no evidence of specific or dose-dependent effects of gluten in patients with NCGS placed diets low in fermentable, oligo-, di-, monosaccharides, and polyols."

Gastroenterology 2013: 145(2): 320-328
13 August 2013

Go to top of page Email this page Email this page to a colleague

 02 March 2015

Advanced search
 02 March 2015 
Genes and early diagnosis of IBD
 02 March 2015 
Assessment of GERD
 02 March 2015 
Liver disease in patients awaiting liver transplant
 27 February 2015 
Obesity and weight-loss therapy
 27 February 2015 
MRE performance in staging liver fibrosis
 27 February 2015 
Bleeding in diverticulosis
 26 February 2015 
Familial colorectal cancer risk and primary cancer
 26 February 2015 
Herbal products and the liver
 26 February 2015 
Questionnaires for GERD
 25 February 2015 
Exercise and NAFLD
 25 February 2015 
IBD in Korea
 25 February 2015 
Immunosuppressive therapy and T. whipplei
 24 February 2015 
Clinical trials in pediatric IBD
 24 February 2015 
Reducing health care costs in IBD
 24 February 2015 
GI bleeding after anticoagulation interruption
 23 February 2015 
Visceral abdominal obesity and IBS
 23 February 2015 
Crohn's outcomes with infliximab
 23 February 2015 
Intestinal microbiota and celiac disease
 20 February 2015 
H. pylori eradication
 20 February 2015 
Antiviral treatment and Hep C outcomes
 20 February 2015 
C. diff testing in IBD
 19 February 2015 
Intestinal microbiota in IBS
 19 February 2015 
Peptic ulcer bleeding mortality in liver disease
 19 February 2015 
Fecal microbial transplant in active Crohn's disease
 18 February 2015 
Genetic testing and GI cancers
 18 February 2015 
Placebo analgesia in functional abdominal pain
 18 February 2015 
Successful Hep C virus therapy
 17 February 2015 
Quality measures and colonoscopist selection
 17 February 2015 
Global incidence of esophageal cancer
 17 February 2015 
Anti-viral treatment and survival in Hep C
 16 February 2015 
Saliva for the diagnosis of GERD
 16 February 2015 
H pylori eradication therapy
 16 February 2015 
Medical marijuana for digestive disorders
 13 February 2015 
Beta-blockers in cirrhosis
 13 February 2015 
Liver disease and peptic ulcer bleeding
 13 February 2015 
Prevalence of microscopic colitis
 12 February 2015 
Liver disease in chronic Hep C
 12 February 2015 
Patient-reported outcomes in Hep C
 12 February 2015 
Patientsí colonoscopist selection
 11 February 2015 
Guidelines for the diagnosis of hepatocellular carcinoma
 11 February 2015 
Hepatic decompensation in Hep C cirrhosis
 11 February 2015 
NAFLD and CVD
 10 February 2015 
Percutaneous endoscopic gastrostomy
 10 February 2015 
Factors that influence hepatic steatosis
 10 February 2015 
Gene variants and Crohn's susceptibility
 09 February 2015 
Factors that influence gallstone surgery
 09 February 2015 
Factors associated with increased mortality in cirrhosis
 09 February 2015 
Use of immunomodulators in IBD
 06 February 2015 
Colorectal cancer risk in IBD
 06 February 2015 
H. pylori and peptic ulcer bleeding
 06 February 2015 
IBS and somatization
 05 February 2015 
GERD, dyspepsia and IBS symptoms
 05 February 2015 
Quality of life in Crohn's after antitumor necrosis factor agents
 05 February 2015 
Thalidomide and refractory Crohn's
 04 February 2015 
Telemedicine in IBD
 04 February 2015 
Infliximab and muscle wasting in Crohn's
 04 February 2015 
Resistance mutations in chronic Hep B
 03 February 2015 
Testosterone in advanced liver disease
 03 February 2015 
Mortality in peptic ulcer bleeding
 03 February 2015 
Colonoscopic remission of ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us